Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Pharma's EU Woes Continued In Second Quarter - Where’s The Bottom?

Executive Summary

In addition to patent expiries, which affected pharma company performance globally, ongoing price cuts for drugs and increasing parallel trade continued to hurt pharma’s European performance in the second quarter, with the gloom unlikely to lift soon. What’s at stake is further pharma investment in Europe.

You may also be interested in...

AirFluSal’s Decentralized Approach to EU Shields Seretide From Exposure

Sandoz’ AirFluSal Forspiro has been approved in Germany, but the company’s decentralized route into Europe means that GSK’s Seretide is somewhat shielded from all-out competition.

Second-Quarter Earnings Updates, In Brief

In quarterly earnings calls, GlaxoSmithKline talks acquisition strategy while Regeneron is bullish on the sales prospects for its age-related macular degeneration drug Eylea and Sanofi highlights the recently initiated Phase III ODYSSEY program in hypercholesterolemia.

J&J Under CEO Gorsky Will Remain Diverse But Be More Selective

New CEO Alex Gorsky outlines his vision for the healthcare giant in his first quarterly sales and earnings presentation to investors. Short-term priorities include restoring OTC drug supply and building pharmaceutical sales momentum.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts